Abstract
Familial hypercholesterolemia (FH) is an underdiagnosed disease that contributes to a significant number of cardiovascular incidents through high serum Low-Density Lipoprotein Cholesterol (LDL-C) values. Its treatment primarily requires healthy lifestyle and therapy based on statins, ezetimibe and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); however, there are also new treatment options that can be used in patients who do not respond to therapy, among which we highlight evinacumab. Elevated LDL-C values, together with clinical manifestations associated with cholesterol deposition (e.g., tendon xanthomas, xanthelasma and arcus cornealis) and family history are the main elements in the diagnosis of FH. Pathognomonic signs of FH include extensor tendon xanthomas; however, their absence does not exclude the diagnosis. Elevated LDL-C levels lead to premature Atherosclerotic Cardiovascular Disease (ASCVD), which is why early diagnosis and treatment of FH is essential. Evinacumab, a novelty in pharmacological practice, having a complex mechanism of action, causes desirable changes in lipid parameters in patients with homozygous form of familial hypercholesterolemia (HoFH). This review collects and summarizes the most important aspects of the new drug, especially being a discovery in the treatment of HoFH, giving these patients hope for a longer and more comfortable life.
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference80 articles.
1. National Institute for Health and Care Excellence (NICE) (2019). Familial Hypercholesterolaemia: Identification and Management, National Institute for Health and Care Excellence (NICE).
2. Diagnosis of Familial Hypercholesterolemia;Jialal;Am. J. Clin. Pathol.,2016
3. Homozygous Familial Hypercholesterolemia;Nohara;J. Atheroscler. Thromb.,2021
4. Familial hypercholesterolemia treatments: Guidelines and new therapies;Raal;Atherosclerosis,2018
5. Familial Hypercholesterolemia in Children and Adolescents: Diagnosis and Treatment;Maliachova;Curr. Pharm. Des.,2018
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献